Measurement of Serum Brain Natriuretic Peptide Level as a Biomarker for Congestive Heart Failure

Objective To explore the value of Brain Natriuretic peptide(BNP)in estimating the degree of seriousness of congestive heart failure(HF)and study BNP level of CHF caused by various cardiovascular diseases.Methods 100 patients with CHF were divided into three classes(class Ⅰ,Ⅱ and Ⅳ)by New York Heart Association(NYHA)functional classification Standard.100 healthy individuals were selected into control group.Serum BNP concentration were measured by electrochemical luminescence assay(Elecsys 2010,Roche Diagnostics).Results Mean serum BNP concentration of patients with CHF was 4 745.49±3 698.70 ng/ml,which was higher significantly than that of normal control(66.18±44.30ng/ml).Moreover,the growth in BNP level was increased with NYHA functional classification:class Ⅳ(1 0251±9 326.8 ng/ml)class Ⅲ(1 239±1 063.8 ng/ml)class Ⅱ(167.4±143.4 ng/ml),which was statistically significant(P0.05).It was statistically significant among three groups of pathogenesis(hypertension,coronary heart disease and rheumatic heart disease)of CHF in the NYHA classification level Ⅱ,whereas there was no difference between class Ⅲ and class Ⅳ.Conclusion Serum BNP level can be applied as a biomarker for congestive heart failure and can estimate the severity of CHF.